CPC A61K 35/17 (2013.01) [A61P 3/00 (2018.01); A61P 7/06 (2018.01); A61P 21/00 (2018.01); A61P 35/02 (2018.01); A61P 37/02 (2018.01); C12N 5/0087 (2013.01); C12N 5/0636 (2013.01); C12N 5/0637 (2013.01); C12N 5/0638 (2013.01); C12N 5/0646 (2013.01); C12N 5/0647 (2013.01)] | 21 Claims |
1. A therapeutic composition comprising one or more unit doses of a cellular graft, wherein each unit dose of the cellular graft comprises a population of cells that is enriched for:
CD25+ regulatory T cells (Tregs); and
CD45RA− memory T cells (Tmems);
wherein the population of cells is depleted of CD45RA+CD25− naïve conventional αβ-T cells; wherein the population of cells comprises a ratio of CD45RA+CD25− naïve conventional αβ-T cells to CD25+ Tregs that is less than 1:5; wherein said therapeutic composition further comprises one or more pharmaceutically acceptable excipients; and wherein said therapeutic composition has a reduced incidence of Graft versus Host Disease (GVHD) following administration to a subject compared to administration of a composition comprising the ratio of CD45RA+CD25− naïve conventional αβ-T cells to CD25+ Tregs present in an unprocessed biological sample.
|